



OPEN ACCESS

EDITED BY

Paras Nath Yadav,
Tribhuvan University, Nepal

REVIEWED BY

Hongmei Cui,
Lanzhou University, China
Xiuping Yu,
Louisiana State University Health
Shreveport, United States

*CORRESPONDENCE

Hong-Wu Chen,
✉ hwzchen@ucdavis.edu

RECEIVED 17 January 2023

ACCEPTED 04 April 2023

PUBLISHED 26 April 2023

CITATION

Zou H, Yang Y and Chen H-W (2023),
Natural compounds ursolic acid and
digoxin exhibit inhibitory activities to
cancer cells in ROR γ -dependent and
-independent manner.
Front. Pharmacol. 14:1146741.
doi: 10.3389/fphar.2023.1146741

COPYRIGHT

© 2023 Zou, Yang and Chen. This is an
open-access article distributed under the
terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Natural compounds ursolic acid and digoxin exhibit inhibitory activities to cancer cells in ROR γ -dependent and -independent manner

Hongye Zou¹, Yatian Yang¹ and Hong-Wu Chen^{1,2,3*}

¹Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, Sacramento, CA, United States, ²UC Davis Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, United States, ³VA Northern California Health Care System, Mather, CA, United States

Natural compounds ursolic acid (UA) and digoxin isolated from fruits and other plants display potent anti-cancer effects in preclinical studies. UA and digoxin have been at clinical trials for treatment of different cancers including prostate cancer, pancreatic cancer and breast cancer. However, they displayed limited benefit to patients. Currently, a poor understanding of their direct targets and mechanisms of action (MOA) severely hinders their further development. We previously identified nuclear receptor ROR γ as a novel therapeutic target for castration-resistant prostate cancer (CRPC) and triple-negative breast cancer (TNBC) and demonstrated that tumor cell ROR γ directly activates gene programs such as androgen receptor (AR) signaling and cholesterol metabolism. Previous studies also demonstrated that UA and digoxin are potential ROR γ antagonists in modulating the functions of immune cells such as Th17 cells. Here we showed that UA displays a strong activity in inhibition of ROR γ -dependent transactivation function in cancer cells, while digoxin exhibits no effect at clinically relevant concentrations. In prostate cancer cells, UA downregulates ROR γ -stimulated AR expression and AR signaling, whereas digoxin upregulates AR signaling pathway. In TNBC cells, UA but not digoxin alters ROR γ -controlled gene programs of cell proliferation, apoptosis and cholesterol biosynthesis. Together, our study reveals for the first-time that UA, but not digoxin, acts as a natural antagonist of ROR γ in the cancer cells. Our finding that ROR γ is a direct target of UA in cancer cells will help select patients with tumors that likely respond to UA treatment.

KEYWORDS

ursolic acid, digoxin, RAR-related orphan receptor gamma (ROR γ), prostate cancer, breast cancer, context-dependent, natural products (NP)

1 Introduction

Natural products isolated from plants or microorganisms are excellent sources for novel drug discovery (Lin et al., 2020; Atanasov et al., 2021). These naturally active products have relatively high oral bioavailability, special biological activities and known insights of safety and efficacy. Among the natural products, ursolic acid (UA) and digoxin have been reported to possess anti-cancer activity by disrupting multiple signaling pathways. UA is a pentacyclic triterpenoid presented in plants, fruits and herbs, including apple, basil and rosemary. It can inhibit NF- κ B and STAT3 signaling (Shanmugam et al., 2011b; Shanmugam et al., 2012), and

activate JNK-mediated apoptosis (Zhang et al., 2010b) in prostate cancer cells and tumors. UA also downregulates STAT3 (Sathya et al., 2014) and FoxM1 (Wang et al., 2012) signaling pathways in breast cancer cells. Digoxin can be isolated from foxglove plant. It potently inhibits the sodium potassium adenosine triphosphatase (Na⁺/K⁺ + ATPase) and is clinically used for heart diseases, including atrial fibrillation and heart failure. Recent studies suggest that digoxin can display anti-proliferation activity in cells of prostate cancers and breast cancers (Platz et al., 2011; Busonero et al., 2020). Both UA and digoxin have been evaluated in ongoing or completed clinical trials for treatment of several types of cancer. However, their direct targets in cancer cells and tumors remained unclear.

UA has been reported as an inhibitor of amyloid β interaction with its receptor CD36 (Wilkinson et al., 2011). Largely based on results from reporter gene assays, UA was also characterized as modulators of members of the nuclear receptor (NR) family of transcription factors, specifically as agonist of PPAR α (Jia et al., 2011), and antagonist of LXR α (Lin et al., 2018) and ROR γ t, a T cell-specific isoform of ROR γ (Xu et al., 2011). UA strongly reduces IL-17 expression in naïve CD4⁺ T cells and blocks the differentiation of T helper 17 (Th17) cells. Interestingly, UA does not appear to modulate the function of ROR α , which is another member of the ROR subfamily of NR. In an early search for modulators of ROR γ t, digoxin was also shown to possess antagonistic activities to ROR γ t in Th17 cells (Huh et al., 2011). Thus, UA and digoxin are the two major natural compounds that were identified as modulators of ROR γ t in the early studies (Huh et al., 2011; Xu et al., 2011).

Recently, in search for alternative therapeutic targets for advanced cancer, ROR γ in tumor cells was identified to play a critical role in tumor progression in certain types of cancer (Zou et al., 2022a), including castration-resistant prostate cancer (CRPC) (Wang et al., 2016; Wang et al., 2020; Zheng et al., 2020; Zhang et al., 2021), triple-negative breast cancer (TNBC) (Cai et al., 2019; Zou et al., 2022b), small cell lung carcinoma (SCLC) (Chen et al., 2022) and pancreatic ductal adenocarcinoma (PDAC) (Lytle et al., 2019). In CRPC tumors and cells, ROR γ directly activates androgen receptor (AR) expression and AR signaling (Wang et al., 2016; Zheng et al., 2020; Zhang et al., 2021). In TNBC cells and tumors, ROR γ acts as a master activator of tumor cholesterol biosynthesis program (Cai et al., 2019; Zou et al., 2022b). Pharmacological and genetic inhibition of ROR γ strongly block prostate cancer (PCa) and TNBC cell growth and metastasis, suggesting that ROR γ is a novel therapeutic target for cancer (Wang et al., 2016; Cai et al., 2019; Wang et al., 2020; Zheng et al., 2020; Zhang et al., 2021; Zou et al., 2022b).

Although a large number of synthetic, small-molecule modulators of ROR γ /ROR γ t have been identified (Pandya et al., 2018; Zou et al., 2022a), few studies made a direct comparison of their activities. Recently, it was reported that structurally distinct, small-molecule modulators can display large differences in their activities in altering the function of ROR γ /ROR γ t in control of its target gene expression (Zou et al., 2022b). Here we examined the activities of UA and digoxin in cells of PCa and TNBC where the function of ROR γ is relatively defined (Wang et al., 2016; Cai et al., 2019). We found that UA but not digoxin disrupted the previously defined, ROR γ -targeted gene programs. Our results demonstrate that UA,

not digoxin, acts as a natural antagonist of ROR γ in PCa and TNBC cells.

2 Materials and methods

2.1 Cell culture

C4-2B, 22RV1, LNCaP, PC3 and HCC70 cells were cultured in RPMI1640 (Corning) supplemented with 10% FBS. DU145 and MDA-MB-468 cells were cultured in DMEM (Corning) supplemented with 10% FBS. Cells were grown at 37 °C in 5% CO₂ incubators. Cells were obtained from ATCC and were regularly tested being negative for *mycoplasma*.

2.2 Chemicals

XY018 (purity >99%) was synthesized by WuXi AppTec. Ursolic acid (purity >95%) and digoxin (purity >98%) were purchased from Cayman.

2.3 Cell viability, proliferation and colony formation

For cell viability, cells were seeded in 96-well plates at 1000–2000 cells per well in a total volume of 100 μ l of media. After 4 days of incubation of compounds, Cell-Titer Glo reagents (Promega) were added, and luminescence was measured on Varioskan™ LUX multimode microplate reader (Thermo Scientific), according to the manufacturer's instructions. All experimental points were set up in triplicate, and the entire experiments were repeated three times. The estimated *in vitro* IC₅₀ values were calculated by using GraphPad Prism 9 software. For cell proliferation, cells were seeded in 6-well plates at 2 \times 10⁵ per well and treated as indicated. Total viable cell numbers were counted using Countess™ II Automated Cell Counter (Invitrogen). For colony formation assay, 500 cells were seeded in a well of 6-well plate and cultured for 21 days with the medium changing every 5 days. When the cell clone grew visible, the medium was removed, and the cells were fixed with 10% formalin for 10 min. The plated were washed with PBS for two times, and cell colonies were stained with 0.2% crystal violet (in 10% formalin) for 30 min. The above assays were performed in duplicates, and the entire experiments were repeated three times.

2.4 Luciferase reporter gene assay and plasmid transfection

Transient transfection and reporter-gene assays were performed as previously described with modification (Zou et al., 2022b). Briefly, cells were co-transfected with pLX304-ROR γ or empty vector and 7 X RORE reporter plasmid using lipofectamine 3,000 (Cat. L3000015, Invitrogen). Renilla plasmid was co-transfected for normalization. After 12 h of incubation, cells were treated with vehicle or different compounds as indicated for another 24 h. The luciferase activity was analyzed using

Dual-Glo Luciferase Assay System (Promega) on Varioskan™ LUX multimode microplate reader (Thermo Scientific), according to the manufacturer's instructions. All transfections were performed at least in triplicate, and each experiment was repeated three times.

2.5 qRT- PCR and western blotting analysis

Total RNA was isolated from cells using TRIzol™ Reagent (Cat. 15596018, Invitrogen). The cDNA was prepared using qScript™ cDNA SuperMix (Cat. 95048-100, QuantaBio). Quantitative PCR were performed as previously described with modification (Yang et al., 2012). Briefly, cDNAs were mixed with SYBR Green qPCR master mix (Cat. A25742, Applied Biosystems) and gene specific primers. The PCR were performed using the CFX96 Real-Time PCR Detection System (Bio-Rad). The fluorescent values were collected, and fold difference was calculated. *GAPDH* was used as the internal reference to normalize the relative level of each transcript. The experiments were performed at least three times. Primers are listed in Supplementary Table S1.

After cells were lysed, protein concentrations were measured and adjusted using DC™ Protein Assay Kit II (Cat. 5000112, Bio-Rad). Proteins were separated by SDS-PAGE gel and transferred onto PVDF membranes (Cat. IPVH00010, MilliporeSigma). Membranes were incubated with indicated primary antibodies at 4°C overnight and then subjected to second antibody incubation. Antibody-recognized proteins were visualized using ChemiDoc™ MP imaging system (Bio-Rad) after incubation with HRP substrate (Cat. WBLUR0500, MilliporeSigma). Antibodies used are shown in Supplementary Table S2.

2.6 RNA-seq and bioinformatics analysis

HCC70 cells were treated as indicated before RNA extraction. RNA-seq libraries from 1 µg total RNA were prepared and validated as previously described (Yang et al., 2012). Sequencing was performed on an Illumina HiSeq 2000 Sequencer at BGI Tech (Hong Kong). The FASTQ-formatted sequence data were analyzed using a standard BWA-Bowtie-Cufflinks workflow. Briefly, sequence reads were aligned to the reference human genome assembly (hg38) with BWA and Bowtie software. Subsequently, the Cufflinks package (Trapnell et al., 2010). Was applied for transcript assembly and quantification gene expression. To avoid spurious fold levels due to low expression values, only subsets of genes that have expression value of RPKM (reads per kilobase per million mapped reads) or FPKM (fragments per kilobase of exon model per million mapped reads) above 1 for either the vehicle treated cell, or the compound treated cells are included. GSEA was performed using the Java desktop software (<http://www.broadinstitute.org/gsea>) as described previously (Subramanian et al., 2005). Genes were ranked according to the shrunken limma log₂ fold changes and the GSEA tool was used in 'pre-ranked' mode with all default parameters. Previous reported AR-activity signature genes (Asangani et al., 2014) were used in the GSEA analysis.

2.7 ChIP-seq data analysis

ChIP-seq assay was performed as previously described (Cai et al., 2019).

Fastq files from the ChIP-seq were processed by the pipeline of AQUAS Transcription Factor and Histone (https://github.com/kundajelab/chipseq_pipeline). Briefly, sequencing tags were mapped against the *Homo sapiens* (human) reference genome (hg19) by using BWA 0.7.1551. Uniquely mapped tags after filtering and deduping were used for peak calling by model-based analysis for ChIP-Seq (MACS; 2.1.0) to identify regions of enrichment over background. Normalized genome-wide signal-coverage tracks from raw-read alignment files were built by MACS2, UCSC tools (bedGraphToBigWig/bedClip; http://hgdownload.cse.ucsc.edu/admin/exe/linux.x86_64/), and bedTools (<https://github.com/arq5x/bedtools2>). Visualization of the ChIP-seq signal at enriched genomic regions (avgprofile and heatmap) was achieved by using deepTools (<https://deeptools.readthedocs.io/en/develop/index.html>).

2.8 Statistical analysis

Cell culture-based experiments were performed three times or more, with assay points triplicated. The data are presented as mean values ±SD. Statistical analyses were performed by GraphPad Prism software 9.

3 Results

3.1 Ursolic acid (UA) and digoxin differs in effectiveness of killing cancer cells

To compare the anti-growth and -survival activities in cancer cells of UA and digoxin with synthetic ROR γ inhibitors, we included XY018, which was characterized in its activity in antagonizing the function of ROR γ in control of gene programs in the cancer cells and tumors (Wang et al., 2016; Cai et al., 2019; Chen et al., 2022). In the PCa and TNBC cells, UA displayed slightly weaker but comparable inhibitory activity in modulating cell growth and survival when compared to XY018. Specifically, XY018 displayed an IC₅₀ of 2–6 µM in the two PCa cell lines (C4-2B and 22RV1) and the two TNBC cell lines (HCC70 and MDA-MB-468), while UA showed an IC₅₀ of 7–10 µM for the same cell models. On the other hand, Digoxin displayed an IC₅₀ in the sub-micromolar range for both PCa and TNBC cells with IC₅₀ values over 50 fold lower than those of XY018 in the PCa cells (Figure 1A). Similar differences in their effectiveness were observed in assays of cell numeration and cell survival/colony formation assay (Figures 1B,C).

3.2 UA but not digoxin blocks transactivation activity of ROR γ in cancer cells

To examine whether the anti-growth effects of UA and digoxin is associated with their inhibition of ROR γ functions in cancer cells,





FIGURE 1
 UA and digoxin display different effectiveness in inhibition of cancer cell growth when compared to synthetic ROR γ antagonist XY018. (A) The growth inhibition IC₅₀ (μ M) for synthetic ROR γ antagonist XY018, natural ROR γ antagonists ursolic acid and digoxin in indicated PCa and TNBC cell lines treated for 4 days. (B) C4-2B and HCC70 cells were treated by different ROR γ antagonists as indicated. Viable cells were counted after 4 days. Data are shown as mean \pm SD. *n* = 3. Student's t-test. **p* < 0.05, ***p* < 0.01. (C) 22RV1 and MDA-MB-468 cells were treated by different ROR γ antagonists as indicated. Fourteen days later, representative images of colony formation were taken (top) and colonies were counted (bottom). Data are shown as mean \pm SD. *n* \geq 3. Student's t-test. ***p* < 0.01.

we performed luciferase reporter assay in different cancer cells. In PCa (C4-2B and 22Rv1) and TNBC cells (HCC70), UA diminished the ROR γ -dependent activation of the reporter in a concentration-

dependent manner (Figure 2A). Specifically, more than 70% inhibition of its transactivation was observed when cells were treated with 1 μ M UA. However, no significant inhibitory effect



was observed when cells were treated with digoxin (Figure 2A) at concentrations that display potent cell growth inhibition as shown in Figure 1. Additionally, the protein expression of RORγ remained

unchanged when cells were treated with UA or digoxin (Figure 2B). Together, these data suggest that UA and digoxin may inhibit cancer cell growth through RORγ-dependent and -independent mechanisms.

3.3 UA but not digoxin disrupts RORγ-mediated AR expression and AR signaling

In our previous studies, we demonstrated that RORγ directly activates AR gene expression and that synthetic RORγ antagonists reduce the expression of AR and its variant AR-V7 and AR-controlled gene programs in PCa cell lines and tumors (Wang et al., 2016; Zhang et al., 2021). To further examine whether the anti-growth effect of UA in PCa is through RORγ, we performed RNA-seq analysis of C4-2B cells treated by 10 μM UA. Gene-set enrichment analysis (GSEA) showed that an AR target gene signature gene set (Asangani et al., 2014) was significantly disrupted by UA treatment at 24 and 48 h (Figure 3A, top panels). In contrast, 48 h of digoxin treatment significantly enhanced the expression of the AR target gene signature (Figure 3A bottom right panel). Indeed, although some of the previously classified androgen-induced genes such as *KLK2* and *KLK3* (Asangani et al., 2014) were inhibited by both UA and digoxin treatment, *AR* and other AR-regulated genes like *FKBP5* were downregulated by UA while upregulated by digoxin treatment (Figure 3B). Consistent with RNA-seq analysis, UA reduced protein expressions of AR and its variant AR-V7 in C4-2B and 22RV1 cells. Conversely, digoxin treatment had no effects or slightly increased AR expression in C4-2B or 22RV1 cells, respectively (Figure 3C).

3.4 UA displays potent anti-proliferation activity in AR-positive but not AR-negative PCa cells

To further examine whether UA inhibits PCa cell growth through disrupting AR signaling, we compared the anti-cancer effects of UA and digoxin in AR-positive and -negative PCa cells. As expected, UA showed significant stronger inhibitory activity in AR-positive PCa cells compared to AR-negative PCa. Specifically, 5 and 7.5 μM of UA was sufficient to strongly inhibit AR-positive LNCaP and 22RV1 cell growth, while 10 μM of UA had little or no effect on AR-negative DU145 and PC3 cell proliferation (Figure 4A). In contrast, digoxin displayed similar anti-growth effects in both AR-positive and AR-negative PCa cell lines (Figure 4B). In line with the cell growth effects, UA treatment potentially reduced the protein expressions of key cell proliferation genes, including *C-MYC*, *Cyclin A*, *Cyclin D1* and *Cyclin E* in LNCaP, but not in AR-negative PCa cell lines (PC3 and DU145). Additionally, expressions of critical cell apoptosis genes including cleaved *Caspase-3* and *-7* were induced by UA treatment in LNCaP cell and not in PC3 and DU145 cells. (Figure 4C). On the other hand, digoxin downregulated expressions of key cell cycle genes in all 3 cell lines tested (Figure 4D). Together, these data suggest that the anti-cancer PCa cell growth effects of UA is through its inhibition of RORγ function in control of AR-signaling pathway.




FIGURE 3

UA but not digoxin inhibits AR expression and AR-signaling in PCa cells. (A). GSEA of the AR signaling pathway in C4-2B cell treated with UA (10 μM) or digoxin (100 nM) for 24 or 48 h. NES, normalized enrichment score. FDR, false-discovery rate. (B). Heat map display of fold changes (in log₂) of AR-signature gene mRNA analyzed by RNA-seq in C4-2B cell treated with UA (10 μM) or digoxin (100 nM) for 24 or 48 h. (C). Immunoblotting of AR (full length) in C4-2B cell, AR (full length) and AR-V7 in 22RV1 cell treated with UA or digoxin at indicated concentration for 48 h (left). Quantification of Western blotting (right). AR expressions were normalized to that of GAPDH. Data are shown as mean ± SD. n ≥ 3. Student's t-test. **p < 0.01.

3.5 UA not digoxin alters RORγ-controlled expression of cell cycle and apoptosis genes

To further elucidate the effects of UA on RORγ function in cancer cells, we analyzed RNA-seq data we obtained from TNBC cells treated by UA and our ChIP-seq data of RORγ genome occupancy in TNBC cells (Cai et al., 2019). Our analysis revealed

a strong overlap between genes with altered expression by UA and genes that displayed RORγ ChIP-seq peaks. Specifically, 30.7% of genes downregulated by UA displayed reduced RORγ ChIP-seq peaks after the antagonist XY018 treatment (Figure 5A), whereas 33.3% of genes upregulated by UA had increased RORγ ChIP-seq peaks after XY018 treatment (Figure 5B). Gene ontology (GO) analysis of genes with both




FIGURE 4

UA exhibits stronger inhibitory activity in AR-positive PCa compared with AR-negative PCa. (A, B) AR-positive PCa cells (LNCaP and 22RV1) and AR-negative PCa cells (PC3 and DU145) were treated by UA (A) or digoxin (B) at indicated concentrations. One, two and 3 days later, viable cells were counted. (C, D) AR-positive PCa cell (LNCaP) and AR-negative PCa cells (PC3 and DU145) were treated by UA (A) or digoxin (B) at indicated concentrations. Two days later, cells were harvested for Western blotting analysis of indicated proteins. Representative blots, $n = 3$.

reduced expression and ChIP-seq peaks revealed that DNA replication and cell proliferation/division were among the most enriched programs with representative genes such as *POLA1*, *MCM6* and *MKI67* (Figures 5C,E, top panels). On the other hand, apoptotic process was one of the most enriched programs among genes being both UA-increased in expressions and XY018-increased in ChIP-seq peaks (e.g., *BNIP3*, *BMF* and *BIK*) (Figures 5D,E, bottom panels). Our further RNA-seq and qRT-PCR analyses showed that the mRNA expression of ROR γ direct target genes involved in cell cycle/cell proliferation was reduced by both XY018 and UA, while genes involved in apoptosis were induced. In contrast, digoxin displayed either little or no effect at 24 h, or mostly activating effects at 48 h on those genes particularly those of the cell cycle/proliferation (Figure 5F). Together, the results suggest that like antagonist

XY018, UA alters the expression of genes that are direct targets of ROR γ whereas the effects of digoxin on gene expression in TNBC cells do not support the notion that digoxin acts through ROR γ .

3.6 UA not digoxin suppresses ROR γ -mediated cholesterol biosynthesis gene program

Our previous study demonstrated that ROR γ directly controls cholesterol biosynthesis gene expression in TNBC cells (Cai et al., 2019). To further validate that UA but not digoxin targets ROR γ -mediated signaling in TNBC, we analyzed the effects of UA and digoxin on cholesterol biosynthesis gene expression in HCC70 cells. Our RNA-seq and qRT-PCR analysis showed that UA treatment




FIGURE 5


Expression of ROR γ -controlled cell cycle and apoptosis genes was altered by UA but not digoxin in TNBC cells. (A, B) Venn diagram of number of genes with altered ROR γ ChIP-peaks overlapped with genes altered by UA treatment. (C, D) Gene ontology analysis of genes with both reduced (C) or increased (D) expression and ROR γ ChIP-peaks as shown in (A) or (B, E). Heat map display of fold changes (in log 2) of ROR γ direct target cell cycle and apoptosis gene mRNA in HCC70 cells analyzed by RNA-seq (UA) or qPCR (XY018 and digoxin) at indicated condition. (F) ChIP-seq signal visualization of ROR γ at representative cell cycle and apoptosis genes in HCC70 cells treated with 2.5 μ M of XY018 or vehicle for 24 h.

downregulated the expression of the majority of cholesterol-biosynthesis genes including those of the rate-limiting or key enzymes such as HMGCS1, HMGCR, MVK and SQLE. In contrast, digoxin upregulated their expression (Figure 6A). Indeed, GSEA showed that cholesterol-biosynthesis gene programs were significantly disrupted by UA treatment after 24 h of treatment (Figure 6B). Western blotting analysis also confirmed that protein expression of some of the key cholesterol-biosynthesis enzymes such as HMGCS1, HMGCR and SQLE were potently inhibited by UA treatment while remained unchanged when treated with digoxin (Figure 6C). Together with the other data in this study (Figures 2, 5), these results strongly suggest that the anti-tumor

effects of UA but not digoxin in TNBC is at least partially through its inhibition of ROR γ -mediated signaling.

4 Discussion

Digoxin, also known as digitalis, is prescribed to treat heart conditions. Its well-known mechanism of action (MOA) is its inhibition of Na⁺/K⁺ ATPase in the myocardium (Ren et al., 2021). Recent studies also demonstrated that digoxin can modulate several cellular signaling pathways including NF- κ B (Wang et al., 2017) or EGFR-STAT3 signaling (Lin et al., 2015).



In an early search for RORγ ligands, digoxin was claimed as a natural RORγt inverse agonist/antagonist in Th17 immune cells (Huh et al., 2011). Several later studies also showed that 5–10 μM of digoxin can suppress RORγt-mediated Th17 differentiation and IL-17 production (Fujita-Sato et al., 2011; Xiao et al., 2014; Lee et al., 2015). However, results from our study using cancer cell models do not support the conclusion that digoxin, at concentrations that are comparable to its use as an anti-cancer agent, can act as RORγ antagonist. We demonstrated in PCa cells that, at sub-micromolar concentrations, digoxin has modest but significant activating effects on the expression of RORγ direct target gene AR and AR signaling genes. Likewise, in TNBC cells, the expression of cell cycle and cholesterol biosynthesis gene programs that are directly activated by RORγ are also induced by digoxin treatment. These results strongly argue against the notion that digoxin can act as an RORγ antagonist in cancer cells. In fact, our finding is consistent with a recent study showing that digoxin can act as an RORγ agonist and induce RORγt-dependent transcription at sub-micromolar concentrations in the cells examined (Karaś et al., 2019). However, considering that digoxin can target Na⁺/K⁺ ATPase (Ren et al., 2021) and regulate other pathways (Lin et al., 2015;

Wang et al., 2017), further studies are needed to determine whether any of the effects of digoxin in the cancer cells is through RORγ or other pathways.

Unlike digoxin, in this study we found that UA strongly inhibits the expression of AR, a direct target of RORγ in PCa cells. In our RNA-seq analysis, we revealed that UA can inhibit the expression of AR signaling genes that are positively regulated by AR (Asangani et al., 2014), consistent with our previous finding that RORγ stimulates the AR signaling gene program. In addition, we found that the strong anti-proliferation effect of UA can be observed only in AR-positive PCa cells but not AR-negative cells. These data together strongly suggested that the effects by UA treatment on AR expression and signaling is likely through its inhibition of RORγ function in the PCa cells. Several studies showed that UA can inhibit cancer cell and tumor growth by interfering with cell cycle, proliferation, apoptosis, inflammation, angiogenesis, and metastasis (Iqbal et al., 2018; Kornel et al., 2022; Zafar et al., 2022). However, there has been no evidence showing that UA can affect AR expression and/or AR signaling, which is the key driver of PCa development and progression. Of note, inhibition of AR by UA can be observed as low as 10 μM of UA, while the effects

by UA on the other processes were reported at much higher concentration (20–50 μM) of UA (Zhang et al., 2010a; Shanmugam et al., 2011a; Shanmugam et al., 2011b; Li et al., 2022). Thus, it is possible that in PCa cells, disruption of AR signaling through inhibition of ROR γ is the primary MOA of UA.

UA has been shown to display anti-growth effects in cells of different cancers, including prostate cancer, breast cancer, lung cancer, colorectal cancer, and pancreatic cancer (Khwaza et al., 2020; Zafar et al., 2022). However, the direct target of UA in cancer cells remains unclear. Our study here demonstrated in PCa and TNBC cells that UA inhibits the expression of gene programs such as AR signaling and cholesterol biosynthesis that are directly controlled by ROR γ . Our integrated analysis of ChIP-seq and ATAC-seq data also revealed that gene programs affected by UA correlate closely with the ones directly controlled by ROR γ in the cancer cells. Together, these results strongly support the conclusion that in the cancer cells, UA can act as an antagonist to ROR γ . Although previous studies showed that UA can act as ROR γ inhibitor in immune cells such as Th17 cells (Xu et al., 2011; Baek et al., 2014), our study here provides for the first-time evidence that UA displays ROR γ antagonism activity in cancer cells. Similar to UA, recent studies identified additional natural compounds such as elaiophyllin (Zheng et al., 2020) and N-hydroxyapiosporamide (Chen et al., 2022) as ROR γ antagonists. Despite their structural differences, these natural compounds share similar inhibitory effects on the gene programs controlled by ROR γ in the cancer cells and tumors. Given that natural agents often possess effects on multiple cellular and molecular targets, it is critical that thorough investigations are performed to better understand their MOA in order to further develop them for effective clinical use.

Data availability statement

The raw data generated in the study has been deposited in the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>), under accession number GSE230039.

Author contributions

HZ and H-WC contributed to the conception and design of the study. HZ designed and performed the experiments. YY performed bioinformatics analysis. HZ and YY performed data analysis and

data interpretation. HZ wrote the first draft of the manuscript. All authors contributed to the manuscript revision and approved the submitted version.

Funding

This work was supported in part by grants from the NIH (R01 CA206222 and R01CA224900), the Prostate Cancer Foundation (16CHAL02), and the US Department of Veterans Affairs, Office of Research and Development BL&D (I01 BX004271) to H-WC.

Acknowledgments

We thank members of the Genomics Shared Resources of UC Davis Cancer Center for their technical help. The UC Davis Cancer Center Genomics Shared Resource is funded by the UCD Comprehensive Cancer Center Support Grant (CCSG) awarded by the NCI P30 CA093373.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2023.1146741/full#supplementary-material>

References

- Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., et al. (2014). Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. *Nature* 510 (7504), 278–282. doi:10.1038/nature13229
- Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., and Supuran, C. T. International Natural Product Sciences Taskforce (2021). Natural products in drug discovery: Advances and opportunities. *Nat. Prod. Drug Discov. Adv. Oppor.* 20 (3), 200–216. doi:10.1038/s41573-020-00114-z
- Baek, S. Y., Lee, J., Lee, D. G., Park, M. K., Lee, J., Kwok, S. K., et al. (2014). Ursolic acid ameliorates autoimmune arthritis via suppression of Th17 and B cell differentiation. *Acta Pharmacol. Sin.* 35 (9), 1177–1187. doi:10.1038/aps.2014.58
- Busonero, C., Leone, S., Bianchi, F., Maspero, E., Fiocchetti, M., Palumbo, O., et al. (2020). Ouabain and digoxin activate the proteasome and the degradation of the ER α in cells modeling primary and metastatic breast cancer. *Cancers* 12 (12), 3840. doi:10.3390/cancers12123840
- Cai, D., Wang, J., Gao, B., Li, J., Wu, F., Zou, J. X., et al. (2019). ROR γ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. *Nat. Commun.* 10 (1), 4621. doi:10.1038/s41467-019-12529-3
- Chen, J., Hu, Y., Zhang, J., Wang, Q., Wu, X., Huang, W., et al. (2022). Therapeutic targeting ROR γ with natural product N-hydroxyapiosporamide for small cell lung cancer by reprogramming neuroendocrine fate. *Pharmacol. Res.* 178, 106160. doi:10.1016/j.phrs.2022.106160
- Fujita-Sato, S., Ito, S., Isobe, T., Ohyama, T., Wakabayashi, K., Morishita, K., et al. (2011). Structural basis of digoxin that antagonizes ROR γ t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production. *J. Biol. Chem.* 286 (36), 31409–31417. doi:10.1074/jbc.M111.254003

- Huh, J. R., Leung, M. W., Huang, P., Ryan, D. A., Krout, M. R., Malapaka, R. R., et al. (2011). Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing ROR γ t activity. *Nature* 472 (7344), 486–490. doi:10.1038/nature09978
- Iqbal, J., Abbasi, B. A., Ahmad, R., Mahmood, T., Kanwal, S., Ali, B., et al. (2018). Ursolic acid a promising candidate in the therapeutics of breast cancer: Current status and future implications. *Biomed. Pharmacother.* 108, 752–756. doi:10.1016/j.biopha.2018.09.096
- Jia, Y., Bhuiyan, M. J., Jun, H. J., Lee, J. H., Hoang, M. H., Lee, H. J., et al. (2011). Ursolic acid is a PPAR- α agonist that regulates hepatic lipid metabolism. *Bioorg Med. Chem. Lett.* 21 (19), 5876–5880. doi:10.1016/j.bmcl.2011.07.095
- Karaš, K., Salkowska, A., Sobalska-Kwapis, M., Walczak-Drzewiecka, A., Strapagiel, D., Dastyk, J., et al. (2019). Digoxin, an overlooked agonist of rory/ror γ t. *Front. Pharmacol.* 9. doi:10.3389/fphar.2018.01460
- Khwaza, V., Oyediji, O. O., and Aderibigbe, B. A. (2020). Ursolic acid-based derivatives as potential anti-cancer agents: An update. *Int. J. Mol. Sci.* 21 (16), 5920. doi:10.3390/ijms21165920
- Kornel, A., Nadile, M., and Tsiani, E. (2022). Evidence of the beneficial effects of ursolic acid against lung cancer. *Molecules* 27 (21), 7466. doi:10.3390/molecules27217466
- Lee, J., Baek, S., Lee, J., Lee, J., Lee, D.-G., Park, M.-K., et al. (2015). Digoxin ameliorates autoimmune arthritis via suppression of Th17 differentiation. *Int. Immunopharmacol.* 26 (1), 103–111. doi:10.1016/j.intimp.2015.03.017
- Li, S., Wu, R., Wang, L., Dina Kuo, H.-C., Sargsyan, D., Zheng, X., et al. (2022). Triterpenoid ursolic acid drives metabolic reprogramming and epigenetic reprogramming in treatment/prevention of human prostate cancer. *Mol. Carcinog.* 61 (1), 111–121. doi:10.1002/mc.23365
- Lin, S.-R., Chang, C.-H., Hsu, C.-F., Tsai, M.-J., Cheng, H., Leong, M. K., et al. (2020). Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence. *Br. J. Pharmacol.* 177 (6), 1409–1423. doi:10.1111/bph.14816
- Lin, S. Y., Chang, H. H., Lai, Y. H., Lin, C. H., Chen, M. H., Chang, G. C., et al. (2015). Digoxin suppresses tumor malignancy through inhibiting multiple src-related signaling pathways in non-small cell lung cancer. *PLoS One* 10 (5), e0123305. doi:10.1371/journal.pone.0123305
- Lin, Y. N., Wang, C. C. N., Chang, H. Y., Chu, F. Y., Hsu, Y. A., Cheng, W. K., et al. (2018). Ursolic acid, a novel liver X receptor α (LXR α) antagonist inhibiting ligand-induced nonalcoholic fatty liver and drug-induced lipogenesis. *J. Agric. Food Chem.* 66 (44), 11647–11662. doi:10.1021/acs.jafc.8b04116
- Lytle, N. K., Ferguson, L. P., Rajbhandari, N., Gilroy, K., Fox, R. G., Deshpande, A., et al. (2019). A multiscale map of the stem cell state in pancreatic adenocarcinoma. *Cell* 177 (3), 572–586.e22. doi:10.1016/j.cell.2019.03.010
- Pandya, V. B., Kumar, S., SachchidanandSharma, R., and Desai, R. C. (2018). Combating autoimmune diseases with retinoic acid receptor-related orphan receptor- γ (ROR γ or ROR γ c) inhibitors: Hits and misses. *J. Med. Chem.* 61 (24), 10976–10995. doi:10.1021/acs.jmedchem.8b00588
- Platz, E. A., Yegnasubramanian, S., Liu, J. O., Chong, C. R., Shim, J. S., Kenfield, S. A., et al. (2011). A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. *Cancer Discov.* 1 (1), 68–77. doi:10.1158/2159-8274.cd-10-0020
- Ren, Y., Wu, S., Burdette, J. E., Cheng, X., and Kinghorn, A. D. (2021). Structural insights into the interactions of digoxin and Na⁺/K⁺-ATPase and other targets for the inhibition of cancer cell proliferation. *Molecules* 26 (12), 3672. doi:10.3390/molecules26123672
- Sathya, S., Sudhagar, S., Sarathkumar, B., and Lakshmi, B. S. (2014). EGFR inhibition by pentacyclic triterpenes exhibit cell cycle and growth arrest in breast cancer cells. *Life Sci.* 95 (1), 53–62. doi:10.1016/j.lfs.2013.11.019
- Shanmugam, M. K., Manu, K. A., Ong, T. H., Ramachandran, L., Surana, R., Bist, P., et al. (2011a). Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model. *Int. J. Cancer* 129 (7), 1552–1563. doi:10.1002/ijc.26120
- Shanmugam, M. K., Ong, T. H., Kumar, A. P., Lun, C. K., Ho, P. C., Wong, P. T., et al. (2012). Ursolic acid inhibits the initiation, progression of prostate cancer and prolongs the survival of TRAMP mice by modulating pro-inflammatory pathways. *PLoS One* 7 (3), e32476. doi:10.1371/journal.pone.0032476
- Shanmugam, M. K., Rajendran, P., Li, F., Nema, T., Vali, S., Abbasi, T., et al. (2011b). Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice. *J. Mol. Med. Berl.* 89 (7), 713–727. doi:10.1007/s00109-011-0746-2
- Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., et al. (2005). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* 102 (43), 15545–15550. doi:10.1073/pnas.0506580102
- Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., et al. (2010). Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat. Biotechnol.* 28 (5), 511–515. doi:10.1038/nbt.1621
- Wang, J. S., Ren, T. N., and Xi, T. (2012). Ursolic acid induces apoptosis by suppressing the expression of FoxM1 in MCF-7 human breast cancer cells. *Med. Oncol.* 29 (1), 10–15. doi:10.1007/s12032-010-9777-8
- Wang, J., Zou, J. X., Xue, X., Cai, D., Zhang, Y., Duan, Z., et al. (2016). ROR- γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. *Nat. Med.* 22 (5), 488–496. doi:10.1038/nm.4070
- Wang, T., Xu, P., Wang, F., Zhou, D., Wang, R., Meng, L., et al. (2017). Effects of digoxin on cell cycle, apoptosis and NF- κ B pathway in Burkitt's lymphoma cells and animal model. *Leuk. Lymphoma* 58 (7), 1673–1685. doi:10.1080/10428194.2016.1256480
- Wang, Y., Huang, Z., Chen, C. Z., Liu, C., Evans, C. P., Gao, A. C., et al. (2020). Therapeutic targeting of MDR1 expression by ROR γ antagonists resensitizes cross-resistant CRPC to taxane via coordinated induction of cell death programs. *Mol. Cancer Ther.* 19 (2), 364–374. doi:10.1158/1535-7163.mct-19-0327
- Wilkinson, K., Boyd, J. D., Glicksman, M., Moore, K. J., and El Khoury, J. (2011). A high content drug screen identifies ursolic acid as an inhibitor of amyloid beta protein interactions with its receptor CD36. *J. Biol. Chem.* 286 (40), 34914–34922. doi:10.1074/jbc.M111.232116
- Xiao, S., Yosef, N., Yang, J., Wang, Y., Zhou, L., Zhu, C., et al. (2014). Small-molecule ROR γ t antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. *Immunity* 40 (4), 477–489. doi:10.1016/j.immuni.2014.04.004
- Xu, T., Wang, X., Zhong, B., Nurieva, R. I., Ding, S., and Dong, C. (2011). Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of ROR γ t protein. *J. Biol. Chem.* 286 (26), 22707–22710. doi:10.1074/jbc.C111.250407
- Yang, P., Guo, L., Duan, Z. J., Tepper, C. G., Xue, L., Chen, X., et al. (2012). Histone methyltransferase NSD2/MMSET mediates constitutive NF- κ B signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. *Mol. Cell Biol.* 32 (15), 3121–3131. doi:10.1128/mcb.00204-12
- Zafar, S., Khan, K., Hafeez, A., Irfan, M., Armaghan, M., Rahman, A. U., et al. (2022). Ursolic acid: A natural modulator of signaling networks in different cancers. *Cancer Cell Int.* 22 (1), 399. doi:10.1186/s12935-022-02804-7
- Zhang, X., Huang, Z., Wang, J., Ma, Z., Yang, J., Corey, E., et al. (2021). Targeting feedforward loops formed by nuclear receptor ROR γ and kinase PBK in mCRPC with hyperactive AR signaling. *Cancers* 13 (7), 1672. doi:10.3390/cancers13071672
- Zhang, Y., Kong, C., Wang, L., Li, J., Liu, X., Xu, B., et al. (2010a). Ursolic acid overcomes Bcl-2-mediated resistance to apoptosis in prostate cancer cells involving activation of JNK-induced Bcl-2 phosphorylation and degradation. *J. Cell. Biochem.* 109 (4), 764–773. doi:10.1002/jcb.22455
- Zhang, Y., Kong, C., Zeng, Y., Wang, L., Li, Z., Wang, H., et al. (2010b). Ursolic acid induces PC-3 cell apoptosis via activation of JNK and inhibition of Akt pathways *in vitro*. *Mol. Carcinog.* 49 (4), 374–385. doi:10.1002/mc.20610
- Zheng, J., Wang, J., Wang, Q., Zou, H., Wang, H., Zhang, Z., et al. (2020). Targeting castration-resistant prostate cancer with a novel ROR γ antagonist elaiophyllin. *Acta Pharm. Sin. B* 10 (12), 2313–2322. doi:10.1016/j.apsb.2020.07.001
- Zou, H., Yang, N., Zhang, X., and Chen, H.-W. (2022a). ROR γ is a context-specific master regulator of cholesterol biosynthesis and an emerging therapeutic target in cancer and autoimmune diseases. *Biochem. Pharmacol.* 196, 114725. doi:10.1016/j.bcp.2021.114725
- Zou, H., Yang, Y., Shi, Z., Wu, X., Liu, R., Yu, A. M., et al. (2022b). Nuclear receptor ROR γ inverse agonists/antagonists display tissue- and gene-context selectivity through distinct activities in altering chromatin accessibility and master regulator SREBP2 occupancy. *Pharmacol. Res.* 182, 106324. doi:10.1016/j.phrs.2022.106324